Answers are grounded in this paper and cite their sources.
Copper (Cu) transporting ATPases represent a highly conserved subclass of P-type ATPases with critical roles in Cu export and metalloenzyme synthesis. Despite their important biological roles and association with a wide range of human diseases, no high-affinity small-molecule inhibitors have been described. Here, we identify MKV3 as a small molecule inhibitor of Cu-transporting P-type ATPases that targets a conserved Cu + entry site to the translocation pathway. In silico docking against the Xenopus ATP7B structure revealed a highly conserved pocket suitable for pharmacological inhibition. MKV3 bound human ATP7A and ATP7B with nanomolar affinity, competed with N-terminal metal-binding domains for access to the Cu + entry site, and selectively inhibited Escherichia coli CopA ATPase activity and Cu + transport. Mechanistically, MKV3 blocked chaperone-mediated Cu + delivery to the intramembranous CPC site of CopA that is essential for its transport function. We further identified a single charged P-domain residue that governed MKV3 affinity and potency across species. Functionally, MKV3 phenocopied the genetic loss of Cu + -ATPases in bacteria, fungi, plants, zebrafish, and mammals, impairing copper-dependent enzymes, transporter trafficking, and copper tolerance. These findings establish a conserved, druggable vulnerability in Cu + -ATPases and introduce MKV3 as a broadly active chemical tool to modulate copper homeostasis across biological kingdoms.
No takes yet. Share an insight, caveat, or question.
Shanbhag et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: